⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4742600 | 0.69 | — | — | |
| SCHEMBL9775780 | 0.59 | — | — | |
| SCHEMBL9851237 | 0.59 | — | — | |
| SCHEMBL2264540 | 0.54 | — | — | |
| SCHEMBL19518262 | 0.53 | — | — | |
| SCHEMBL16669881 | 0.52 | — | — | |
| SCHEMBL24061655 | 0.52 | — | — | |
| SCHEMBL14076040 | 0.52 | — | — | |
| SCHEMBL7073707 | 0.50 | — | — | |
| SCHEMBL21401599 | 0.48 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024076873-A1 | HETEROCYCLIC INHIBITORS OF CD73 FOR TREATMENT OF DISEASE | TEON THERAPEUTICS, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024030647-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | THERAS, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| EP-4274583-A2 | METHODS AND COMPOUNDS FOR TREATING FRIEDREICH'S ATAXIA | Design Therapeutics, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| WO-2023183755-A1 | TRICYCLIC PYRIMIDONES | ERASCA, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-4221709-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | Board of Regents, The University of Texas System (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-4221708-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | Board of Regents, The University of Texas System (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-4125815-A1 | THERAPEUTIC COMPOSITIONS | Wintermute Biomedical, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-4121060-A1 | METHOD OF TREATING VIRAL INFECTIONS WITH HEXOSE TYPE MONOSACCHARIDES AND ANALOGS THEREOF | Board of Regents, The University of Texas System (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-4114468-A1 | GLUCOSE TRIPTOLIDE CONJUGATES AND USES THEREOF | The Johns Hopkins University (US) | 2023-01-11 | — | — | EP | disclosed |
| WO-2022271658-A1 | TRICYCLIC KRAS INHIBITORS | ERASCA, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2007011760-A2 | INHIBITORS OF MITOTIC KINESIN | KALYPSYS, INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007011759-A2 | INHIBITORS OF MITOTIC KINESIN | KALYPSYS, INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007011647-A2 | INHIBITORS OF MITOTIC KINESIN KSP | KALYPSYS, INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007011721-A1 | INHIBITORS OF MITOTIC KINESIN | KALYPSYS, INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| WO-2006124874-A2 | INHIBITORS OF B-RAF KINASE | KALYPSYS, INC. (US) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006116355-A1 | ORTHO-TERPHENYL INHIBITORS OF P38 KINASE AND METHODS OF TREATING INFLAMMATORY DISORDERS | KALYPSYS, INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006060424-A2 | INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS | KALYPSYS, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| WO-2006055187-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| EP-1463505-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Abbott Laboratories (US) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003051366-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ABBOTT LABORATORIES (US) | 2003-06-26 | — | — | WO | disclosed |